OMEROS CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that OMEROS CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $22.02M | Mar 1, 2019 |
| FY2018 | Sep 30, 2018 | $4.61M | Mar 1, 2019 |
| FY2018 | Jun 30, 2018 | $1.66M | Mar 1, 2019 |
| FY2018 | Mar 31, 2018 | $1.59M | Mar 1, 2019 |
| FY2018 | Dec 31, 2017 | $13.76M | Mar 1, 2019 |
| FY2018 | Sep 30, 2017 | $21.66M | Mar 1, 2019 |
| FY2018 | Jun 30, 2017 | $17.15M | Mar 1, 2019 |
| FY2018 | Mar 31, 2017 | $12.26M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $12.91M | Mar 1, 2018 |
| FY2017 | Sep 30, 2016 | $11.29M | Mar 1, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $10.63M | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | $26.11M | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | $13.53M | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | $23.54M | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | $33.42M | Mar 1, 2021 |
| FY2020 | Sep 30, 2019 | $29.86M | Mar 1, 2021 |
| FY2020 | Jun 30, 2019 | $26.75M | Mar 1, 2021 |
| FY2020 | Mar 31, 2019 | $21.78M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $22.02M | Mar 2, 2020 |
| FY2019 | Sep 30, 2018 | $4.61M | Mar 2, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.35M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($156.82M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | ($117.81M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $47.42M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $194.24M | Apr 1, 2024 |
| FY2020 | Dec 31, 2020 | ($37.27M) | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | ($38.46M) | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | ($33.29M) | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | ($29.03M) | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | ($29.23M) | Mar 1, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($122.80M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($166.95M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | ($164.53M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | ($163.39M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | ($173.62M) | Apr 1, 2024 |
| FY2020 | Dec 31, 2020 | ($33.82M) | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | ($25.43M) | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | ($27.68M) | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | ($23.68M) | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | ($23.70M) | Mar 1, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $81.30M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $119.52M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $114.87M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $112.72M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $118.78M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $107.61M | Mar 13, 2023 |
| FY2021 | Dec 31, 2019 | $106.32M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $89.86M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $55.60M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $50.70M | Mar 1, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $41.50M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $47.43M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $49.66M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $50.67M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $54.84M | Apr 1, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($116.09M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($148.80M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $74.73M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | ($86.48M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | ($109.72M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | ($100.09M) | Mar 13, 2023 |
| FY2021 | Dec 31, 2019 | ($60.07M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($103.74M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($36.23M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | ($51.50M) | Mar 1, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $65.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $165.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $426.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $113.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $277.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $283.0K | Mar 13, 2023 |
| FY2021 | Dec 31, 2019 | $334.0K | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $567.0K | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $350.0K | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $126.0K | Mar 1, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $325.63M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $277.08M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $378.27M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $590.97M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $419.27M | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | $181.04M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $136.97M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $95.94M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $116.33M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $67.28M | Mar 1, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($121.23M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($182.61M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | ($24.98M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2022 | $85.68M | Mar 31, 2026 |
| FY2024 | Dec 31, 2021 | $23.78M | Mar 31, 2025 |
| FY2023 | Dec 31, 2020 | ($120.75M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2019 | ($109.02M) | Mar 13, 2023 |
| FY2021 | Dec 31, 2018 | ($100.16M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2017 | ($2.81M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2016 | ($37.45M) | Mar 2, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($913.70M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($910.35M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($753.53M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($635.72M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($683.13M) | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | ($872.67M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($734.61M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($650.13M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | ($523.37M) | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | ($469.89M) | Mar 1, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.66M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $3.40M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $7.11M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $11.01M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $100.81M | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | $10.50M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $3.08M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $5.86M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $3.39M | Mar 1, 2019 |
| FY2018 | Dec 31, 2016 | $2.22M | Mar 1, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $87.90M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $164.90M | Mar 31, 2026 |
| FY2023 | Dec 31, 2023 | $213.16M | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $315.29M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $313.46M | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | $236.29M | Mar 1, 2022 |
| FY2017 | Dec 31, 2017 | $83.83M | Mar 1, 2018 |
| FY2016 | Dec 31, 2016 | $80.52M | Mar 16, 2017 |
| FY2016 | Oct 26, 2016 | $70.00M | Mar 16, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Mar 13, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Mar 1, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Mar 31, 2026 |
| FY2022 | Dec 31, 2022 | 0 | Mar 13, 2023 |
| FY2022 | Dec 31, 2021 | 3 | Mar 13, 2023 |
| FY2022 | Dec 31, 2020 | (2) | Mar 13, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Mar 1, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 71.67M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 58.04M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 61.13M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 62.83M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 62.63M | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | 61.67M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 54.20M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 49.01M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | 48.21M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | 43.82M | Mar 1, 2018 |